Harnessing MerTK agonism for targeted therapeutics
Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically sil...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2020-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ff1a7c53d0604dbeb931c27b4bcbd83c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Vivekananda Kedage |e author |
| 700 | 1 | 0 | |a Diego Ellerman |e author |
| 700 | 1 | 0 | |a Yongmei Chen |e author |
| 700 | 1 | 0 | |a Wei-Ching Liang |e author |
| 700 | 1 | 0 | |a Joven Borneo |e author |
| 700 | 1 | 0 | |a Yan Wu |e author |
| 700 | 1 | 0 | |a Minhong Yan |e author |
| 245 | 0 | 0 | |a Harnessing MerTK agonism for targeted therapeutics |
| 260 | |b Taylor & Francis Group, |c 2020-01-01T00:00:00Z. | ||
| 500 | |a 10.1080/19420862.2019.1685832 | ||
| 500 | |a 1942-0870 | ||
| 500 | |a 1942-0862 | ||
| 520 | |a Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically silent. Here, we describe a bispecific antibody approach to harness MerTK for targeted clearance without inducing proinflammatory cytokine release associated with Fcγ receptor engagement. We generated bispecific antibodies targeting live B cells or amyloid beta aggregates to demonstrate the feasibility and versatility of this new approach. | ||
| 546 | |a EN | ||
| 690 | |a Phagocytosis | ||
| 690 | |a bispecific antibody | ||
| 690 | |a immunologically silent | ||
| 690 | |a MerTK | ||
| 690 | |a Fcγ receptor | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n mAbs, Vol 12, Iss 1 (2020) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/19420862.2019.1685832 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0862 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0870 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ff1a7c53d0604dbeb931c27b4bcbd83c |z Connect to this object online. |